Azathioprine-Induced Porto-Sinusoidal Vascular Disease Complicated with Oesophageal Varices in a Crohn’s Disease Patient – Case Report
Journal of Crohn's and Colitis · 20.10.2023 · 17 (9) · 1549-1551
DOI: 10.1093/ecco-jcc/jjad066 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 17.04.2023. Verfasst von Tomotaka Yazaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
To the Editor, Azathioprine [AZA], widely administered as maintenance therapy for Crohn’s disease [CD], is known to have various adverse effects. Recently, cases of AZA-related non-cirrhotic portal hypertension [PH] have been reported, though its occurrence is considered to be rare.1,2 Herein, we report a case of AZA-related porto-sinusoidal vascular disease [PSVD]3 in a patient with CD diagnosed 7 years after beginning AZA administration. A 44-year-old male was diagnosed with ileocolonic CD ~20 years previously. Eight years after that diagnosis, severe stenosis of the terminal ileum developed and an ileocecal resection was performed. Infliximab administration was started, though abdominal pain and diarrhoea appeared approximately 2 years later. Thus, administration of AZA was commenced 3 years after the resection procedure. Approximately 7 years after beginning AZA, severe stenosis of the neo-terminal ileum was revealed. Oesophagogastroduodenoscopy performed as a preoperative examination showed oesophageal varices [EVs] with red colour signs [Figure 1A]. Hepatobiliary enzymatic activities were nearly normal, with no abnormal findings indicating potential chronic liver injury. However, only platelet count gradually decreased from 36.5 × 104 to 10.5 × 104/μL during the approximately 7-year period after starting AZA administration. Additionally, a review of previous abdominal computed tomography images demonstrated splenomegaly with gradual enlargement over time during the same period. As these findings were suggestive of PH, a parenchymal liver biopsy was performed. Histological findings demonstrated dilated sinusoids and mild fibrotic findings from the central vein to portal vein area [Figure 1D–G], suggesting PSVD. No evidence of cirrhotic change of the liver was found. It was considered that PSVD might have been caused by AZA-induced sinusoidal endothelial cell injury, because of the rapid platelet count decrease and splenomegaly after beginning AZA treatment. Thus, administration of AZA was discontinued. Endoscopic therapy for EV contributed to complete eradication [Figure 1B]. To treat the neo-terminal ileum stenosis, a small partial intestinal resection was performed. Two years after discontinuation of AZA, oesophagogastroduodenoscopy revealed EV recurrence [Figure 1C], indicating the existence of prolonged PH even after AZA discontinuation. [A–C] Endoscopic findings before and after endoscopic therapy for oesophageal varices [EV]. [A] Before endoscopic therapy. [B] After endoscopic therapy. Two sessions of endoscopic injection sclerotherapy and variceal ligation contributed to complete eradication of EV. [C] Two years after endoscopic therapy, EV recurrence was noted. [D–G] Histological findings of liver biopsy specimen. [D] Low-power field [LPF] view with haematoxylin-eosin [H-E] staining indicating liver parenchyma. Liver biopsy findings showed no evidence of cirrhosis. [E] High-power field [HPF] view of H-E-stained area [red box in D]. Multiple dilated sinusoids were noted [yellow arrows]. [F] LPF view of area shown by yellow box in A. AZAN staining revealed thin fibrosis from the central vein to portal vein area. [G] HPF view of H-E-stained area [yellow box in D]. Several ceroid-laden macrophages were found in the portal vein area [red arrow]. The definition of PSVD is based absence of cirrhosis with or without signs of PH or histological lesions, and the condition is characterized by obliterative portal venopathy, nodular regenerative hyperplasia, non-cirrhotic portal fibrosis and incomplete septal cirrhosis.3 A retrospective study of drug-related PSVD showed decreased platelet count and splenomegaly as predictive markers for development of EV, with those findings appearing up to 6 months after beginning causative drug administration.4,5 Clinical physicians should be aware of the possibility of AZA-related PSVD, particularly when decreased platelet count and splenomegaly appear after beginning AZA treatment. Furthermore, careful monitoring for potential manifestations of PH should be performed during AZA administration as well as following its discontinuation. T.Y. received lecture fees from Eisai Co., Ltd. outside the submitted work. K.K. received lecture fees from EA Pharma Co., Ltd., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. outside the submitted work. S.I received grants from JIMRO Co., Ltd., EA Pharma Co., Ltd., Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mochida Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., AbbVie Inc, and Chugai Clinical Research Center Co., Ltd. outside the submitted work. Additionally, S.I received lecture fees from EA Pharma Co., Ltd., Asahi Kasei Pharma Corporation, ASKA Pharmaceutical Co., Ltd., AstraZeneca plc, AbbVie Inc, Otsuka Pharmaceutical Co., Ltd., OLYMPUS, JIMRO Co., Ltd., Tsumura & Co., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Gilead Sciences, Inc., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., Janssen Pharmaceutical K.K., and Japan Lifeline Co., Ltd. outside the submitted work. Conception and design: Kousaku Kawashima and Tomotaka Yazaki. Acquisition of data: Tomotaka Yazaki and Kousaku Kawashima. Drafting of the manuscript: Tomotaka Yazaki, Kousaku Kawashima and Shunji Ishihara. Final approval of the version to be published: Shunji Ishihara.
Autor:innen und Institutionen
- Department of Internal Medicine II, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan.
- Division of Hepatology, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan.
- Inflammatory Bowel Disease Center, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan.
ORCID-Profile: Kousaku Kawashima
Zitieren
APA
Yazaki, T., Kawashima, K., & Ishihara, S. (2023). Azathioprine-Induced Porto-Sinusoidal Vascular Disease Complicated with Oesophageal Varices in a Crohn’s Disease Patient – Case Report. Journal of Crohn's and Colitis, 17(9), 1549-1551. https://doi.org/10.1093/ecco-jcc/jjad066
Vancouver
Yazaki T, Kawashima K, Ishihara S. Azathioprine-Induced Porto-Sinusoidal Vascular Disease Complicated with Oesophageal Varices in a Crohn’s Disease Patient – Case Report. Journal of Crohn's and Colitis. 2023;17(9):1549-1551. doi:10.1093/ecco-jcc/jjad066
BibTeX
@article{Yazaki2023,
author = {Yazaki, Tomotaka and Kawashima, Kousaku and Ishihara, Shunji},
title = {Azathioprine-Induced Porto-Sinusoidal Vascular Disease Complicated with Oesophageal Varices in a Crohn’s Disease Patient – Case Report},
journal = {Journal of Crohn's and Colitis},
year = {2023},
volume = {17},
number = {9},
pages = {1549--1551},
doi = {10.1093/ecco-jcc/jjad066}
}
EUVIMED